Pharmaceutical

Nabiximols Improve Spasticity Symptoms in Motor Neuron Disease

By:
On:
In: Neurology, Pharmaceutical

From Neurology Advisor: Nabiximols, a cannabidiol, reduced spasticity symptoms and was tolerable and safe when used in patients with motor neuron disease, according to a phase 2 trial published in Lancet Neurology. In this randomized, double-blind study (ClinicalTrials.gov identifier: NCT01776970), patients with possible, probable, or definite amyotrophic lateral sclerosis orRead More →

Photo of Seattle Image Credit: Margaret Wallace. All Rights Reserved. Unauthorized Reuse Prohibited

By:
On:
In: Pharmaceutical

In another historic first for advancing research into the uses of cannabis for pharmaceutical purposes, the University of Washington (UW) has entered into a deal with Canadian-based Pascal Biosciences. Negotiated by CoMotion, UW’s incubation group, the partnership involves UW licensing a cannabinoid-based compound, ST-403 (ST) for use in various pharma products.Read More →

Revive Therapeutics Granted FDA Orphan Drug Designation

By:
On:
In: Pharmaceutical

According to a recent announcement made by Revive Therapeutics, the company has been granted an FDA Orphan Drug Designation for the use of cannabidiol (“CBD”) in preventing ischemia and reperfusion injury (“IRI”) — both of which can result from solid organ transplantation. Under the Orphan Drug Act of 1983, the FDARead More →

CBD-Derived Epidiolex Gains FDA Approval for Epilepsy

By:
On:
In: Medical, Pharmaceutical

In an historic first, the U.S. Food and Drug Administration approved the drug Epidiolex for the treatment of children with epilepsy. The FDA-approved prescription of Epidiolex is specifically intended for the treatment of two kinds of very severe epilepsy, namely: Dravet  syndrome and Lennox-Gastaut Syndrome. GW Pharmaceuticals, based in the UK, manufactures theRead More →